{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T20:00:54Z","timestamp":1765742454007,"version":"3.37.3"},"reference-count":18,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T00:00:00Z","timestamp":1544572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0208920","type":"journal-article","created":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T13:46:32Z","timestamp":1544622392000},"page":"e0208920","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical outcomes of bortezomib-based therapy in myeloma"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9578-7632","authenticated-orcid":true,"given":"Faouzi","family":"Djebbari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anandagopal","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant","family":"Vallance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaimal","family":"Kothari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,12,12]]},"reference":[{"article-title":"Fast Facts: Multiple Myeloma and Plasma Cell Dyscrasias","year":"2015","author":"K Ramasamy","key":"ref1"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3322\/caac.21252","article-title":"Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back","volume":"64","author":"G Bianchi","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"ref3","unstructured":"Cancer Research UK. Myeloma Statistics. Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/myeloma#heading-Six<\/ext-link> (Accessed: 30 November 2018)"},{"key":"ref4","unstructured":"National Institute for Care and Clinical Excellence. Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation. Available from: https:\/\/www.nice.org.uk\/guidance\/ta311<\/ext-link> (Accessed 24th January 2018)"},{"key":"ref5","unstructured":"National Institute for Care and Clinical Excellence. Bortezomib and thalidomide for the first\u2011line treatment of multiple myeloma. Available from: https:\/\/www.nice.org.uk\/Guidance\/ta228<\/ext-link> (Accessed 24th January 2018)"},{"key":"ref6","unstructured":"National Institute for Care and Clinical Excellence. Bortezomib monotherapy for relapsed multiple myeloma. Available from: https:\/\/www.nice.org.uk\/guidance\/ta129<\/ext-link> (Accessed 24th January 2018)"},{"issue":"5","key":"ref7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"P Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"ref8","article-title":"Efficacy and safety of once weekly bortezomib in multiple myeloma patients","author":"S Bringhen","year":"2010","journal-title":"Blood"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/leu.2016.36","article-title":"A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma","volume":"30","author":"A Larocca","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"ref10","first-page":"679","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"PG Richardson","year":"2010"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma","volume":"359","author":"JF San Miguel","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma","volume":"352","author":"PG Richardson","year":"2005","journal-title":"New England Journal of Medicine"},{"article-title":"The advantages of switch to subcutaneous bortezomib in the real life","year":"2017","author":"S Mangiacavalli","key":"ref13"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"e0123866","DOI":"10.1371\/journal.pone.0123866","article-title":"Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy","volume":"10","author":"J Minarik","year":"2015","journal-title":"PlOS ONE"},{"issue":"4","key":"ref15","first-page":"314","article-title":"Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study","volume":"90","author":"MV Mateos","year":"2015"},{"issue":"33","key":"ref16","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","article-title":"Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens","volume":"33","author":"R Niesvizky","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"13","key":"ref17","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"A Palumbo","year":"2015","journal-title":"Blood"},{"key":"ref18","unstructured":"Introduction to Myeloma. Myeloma UK. 2016. Available at: https:\/\/www.myeloma.org.uk\/wp-content\/uploads\/2015\/12\/An-introduction-to-myeloma-new.pdf<\/ext-link> (last accessed: 12.03.2018)"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0208920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T18:30:30Z","timestamp":1588962630000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0208920"}},"subtitle":[],"editor":[{"given":"Dario","family":"Ummarino","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,12,12]]},"references-count":18,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0208920","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2018,12,12]]}}}